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Abstract
Background: Psoriasis is a chronic inflammatory disorder with an increased risk for coronary artery disease (CAD). This retro-
spective study aimed to evaluate the rate of myocardial ischaemia in patients with psoriasis subjected to myocardial perfusion 
imaging (MPI).
Material and methods: Twelve patients with moderate to severe psoriasis that had MPI were compared to 395 MPIs randomly 
retrieved from our MPIs pool data. All patients had a [99mTc]tetrofosmin stress — rest single-photon emission computer to-
mography ([99mTc]SPECT). Summed difference scores (SDS) were calculated for stress (SSS), rest (SRS) and their difference 
(SDS = SSS – SRS).
Results: There was no significant difference in the frequency of abnormal MPI SPECT outcomes between patients with vs. 
without psoriasis (6/12 vs 214/395 respectively; p = 0.778). From the evaluation of SSS, SRS and SDS, only the SDS scores of 
inadequately compensated resting perfusion defects were significantly lower in patients with psoriasis (p = 0.012). 
Conclusions: Patients with moderate-to-severe psoriasis had a similar rate of abnormal SSS scans compared to control pa-
tients. However, the SDS scans were significantly lower in patients with psoriasis indicating compromised reversibility of resting 
perfusion defects. Larger controlled studies are needed to verify these observations.
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Introduction
Psoriasis is a chronic, recurrent, multifactorial inflammato-
ry skin disorder with a complex co-morbidities profile, which 
includes increased coronary artery disease (CAD) risk [1]. The 
higher prevalence of cardiovascular risk factors is translated into 
a higher CAD burden [2], the higher lifetime risk of a major adverse 
cardiovascular event (MACE) and a higher cardiovascular mortality 
rate, however, the latter only in patients with severe disease and/or 
psoriatic arthritis [3].
Whenever feasible, coronary angiography (CA) remains the 
gold standard for the diagnosis of CAD. Alternatively, non-invasive 
cardiovascular imaging methods are important for the prediction 
of future MACE in patients with CA contraindications. Among 
them, myocardial perfusion imaging (MPI) single photon emission 
computed tomography (SPECT) is probably the modality with the 
highest impact to detect a silent myocardial ischaemic region 
[4]. To date, MPI data has been only occasionally reported in 
patients with psoriasis [5, 6]. This retrospective study aimed to 
evaluate the myocardial status in patients with moderate-to-severe 
psoriasis utilizing MPI. 
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Mann-Whitney U-test; Tab. 2) Psoriatic patients had also increased 
inflammation parameters, C-reactive protein (CRP; average: 10.4) 
and erythrocyte sedimentation rate (ESR; average: 39.1), which 
reflect disease activity. In addition, most patients with psoriasis had 
traditional risk factors for CAD such as increased cholesterol lev-
els and diabetes mellitus and some of them a history of cardiac 
morbidity (Tab. 1). 
There was no significant difference in the frequency of abnormal 
MPI outcomes between patients with vs. without psoriasis (6/12 
vs 214/395 respectively; p = 0.778, Fisher’s exact test) or the 
distributions of the different MPI assessed degrees of myocardial 
ischaemia (p = 0.756; χ2-test). From the 3 parameters of the MPI 
evaluation (SSS, SRS and SDS), only the SDS scores differed 
between patients with and without psoriasis, with SDS being sig-
nificantly lower in patients with psoriasis (p = 0.012, Mann-Whitney 
U-test; Tab. 2 and Fig. 1). Moreover, the above impact of psoria-
sis on the SDS scores was substantiated further by analysing the 
impact of age, sex and psoriasis on the MPI scores with regression 
Table 1. Demographic, clinical and laboratory characteristics of 
n = 12 patients with psoriasis
Range
Mean (SEM1) Min Max
Age (year ) 70.7 (1.8) 56 78
Sex (number) 6 Male / 6 Female
Psoriasis characteristics
PASI 19.2 (2.7) 10 35
Psoriatic arthritis (number) 1 / 12
Acrodermatitis continua (number) 1 / 12
ESR1 (mm/h) 39.1 (5.5) 19 72
CRP1  (mg/l, normal values: 0–6) 10.4 (1.8) 2 20
Elevated CRP (number) 8 /12
Cholesterol (mg/dl) 
Total cholesterol 198.7 (17.9) 87 267
LDL1 116.7 (15.0) 26 176
HDL1 42.0 (3.1) 25 56
LDL / HDL 2.7 (0.3) 1.0 3.6
Triglycerides 205.3 (16.3) 109 255
Glucose (mg/dl) 168.4 (20.2) 92 308
Psoriasis treatment (number) 12/12
Topical psoriasis treatment (number) 12/12
Systemic psoriasis treatment 
(number)
12/12
Systemic per os2 (number) 10/12
Biological3 (number) 10/12
CVD1
Myocardial infarction (number) 2/12
Heart insufficiency (number) 1/12
Aorta insufficiency (number) 2/12
Atrial fibrillation (number) 2/12
1Abbreviations. CRP — C-reactive protein, CVD: cardiovascular disease, ESR 
— erythrocyte sedimentation rate, HDL — high-density lipoprotein, LDL — low-
density lipoprotein, SEM — standard error of the mean. 2acitretin, apremilast 
3Adalimumab, efalizumab, etanercept, infliximab, secukinumab, ustekinumab 
Material and methods
By comparing the medical records of the Nuclear Medicine and 
Dermatology Departments we identified 12 MPIs study outcomes in 
12 patients with a history of moderate-to-severe psoriasis. Since 
the prevalence rate of all psoriasis cases in the reference popu-
lation is approximately 3% [7], we additionally retrieved randomly 
MPI results of 395 patients without psoriasis which formed the 
control group independent of their medical history, cardiac or other 
diseases. Thus, this yielded the study population of 407 patients, 
which included approximately 3% (12/407) of the patient group 
and 97% (395/407) of the control group. The assumption was that 
randomly selected that large control group of patients with other 
medical conditions could better balance any variations in patient 
characteristics between the 2 groups.
All MPIs (inpatients and control individuals) were performed 
after requisition by a cardiologist for a variety of reasons, using 
a 1-day imaging protocol according to published guidelines [8], 
with stress protocol consisted either of a dynamic exercise — Bruce 
protocol treadmill exercise test or a pharmacological exercise with 
dipyridamole or dobutamine. The injected dose was 8 mCi [99mTc] 
tetrofosmin at stress and 20 mCi [99m Tc]tetrofosmin at rest. Forty 
minutes later, the images were acquired via a 90°-angled dual-head 
camera, using a collimator with 64 stops and 25 s per projection 
over a 180° arc. Subsequently, the images were reconstructed 
without attenuation correction as previously reported [9].
Images were visually evaluated by two nuclear medicine 
specialists, applying a 5-point severity scoring scale from normal 
(score = 0) to absent (score = 4) perfusion to a 17 segments polar 
myocardium map as previously reported [10, 11]. 
Summed stress scores (SSS), summed rest scores (SRS) 
and summed difference scores (SDS) was valued for semiquan-
titative visual analysis. Summed scores over the 17 myocardium 
segments (range: 0–64) were evaluated separately for stress [SSS 
reflects both stress-induced and resting perfusion defects (i.e., 
ischaemia + infarct)] and rest (SRS-resting perfusion defects 
(i.e., reflecting scar/hibernating myocardium or artifact]) images. 
In addition, their difference [SDS = SSS – SRS, a measure of 
reversibility in response to exercise or pharmacologic stress, (i.e., 
ischaemia)], was additionally calculated. SSS scores ≥ 4 were 
considered to indicate myocardial ischaemia — (‘pathologic’ MPI), 
graded further as mild (4 ≤ SSS < 9), moderate (9 ≤ SSS < 14) and 
severe for SSS ≥ 4 [12]. Comparisons of traits of interest between 
patients with vs. without psoriasis were quantified by Fisher’s exact, 
χ2- and Mann-Whitney U- tests. The impact of sex (male, female), 
age (‘elderly’, i.e. > 65, versus younger patients) and psoriasis (yes, 
no) on the MPI scores was inferred with ‘generalized linear’ and for 
the dichotomous outcome ‘pathologic’ MPI with logistic regression 
models respectively. All statistical tests were calculated with the 
SPSSv26 software at a significance level p < 0.05. 
Results 
Relevant demographic and laboratory findings of the 12 pso-
riasis patients [6 men and 6 women; mean age: 70.7 years; pso-
riasis area and severity index (PASI) score: 19.2] are summarized 
in Supplementary Table 1. Patients with psoriasis were significantly 
older at the time of MPI (in average about 10 years, p = 0.001, 
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models. Of these three factors, male sex was the most important 
and universal predictor of myocardial ischaemia (Tab. 3). However, 
psoriasis remains a significant independent predictor of the SDS 
(p = 0.023). Finally, older age was a significant predictor only of 
a higher degree of resting perfusion defects (SRS score; p = 0.016). 
Discussion 
To the best of the authors’ knowledge, this is the first report 
of the results of cardiologist’s indicated MPI tests in patients with 
moderate-to-severe psoriasis. The main outcome of this study 
is a comparable prevalence of myocardial ischaemia (around 
50%) in patients with and without psoriasis, even though the 
former patients were significantly older at the time of the MPI 
conduction. However, the compromised myocardial oxygenation 
of the patients with moderate-to-severe psoriasis seems to be al-
ready established at a younger age. Employing MPI Zutt et al. [6], 
found a comparable rate of ischaemia (56%) in 50 prospectively 
examined much younger psoriasis patients (average 49.3 years, 
i.e., about 20 years younger compared to the present cohort) with 
a similar disease burden. In this context, it is worth noting that Yalcin 
et al. [5], reported no pathologic MPI results in 28 much younger 
patients (average age: 41.2 years) with a rather mild psoriasis at 
the time of examination.
Figure 1. Box-plot diagrams of SPECT MPI summed scores of patients with vs. without psoriasis (p: significance; Mann-Whitney U-test);  
A. SSS: ischaemia scores at stress. Dashed line: score limit for ischaemia; B. SRS: ischaemia scores at rest; C. SDS: scores of reversibility of stress 
ischaemia (SDS = SSS – SRS); MPI — myocardial perfusion imaging; SPECT — single photon emission computed tomography
Table 2. Comparison of age at SPECT MPI conduction and SPECT MPI myocardial ischemia scores between patients with psoriasis and controls 
(mean [SEM]; p-values: Mann-Whitney U-test)










SSS1 70.7 [1.80] 60.0 [0.60] 0.001 Not applicable
SRS1 4.92 [1.55] 5.33 [0.26] 0.566 5.10 [1.77] 5.90 [0.49] 0.478
SDS1 4.67 [1.34] 2.91 [0.20] 0.145 4.60 [1.47] 3.75 [0.41] 0.410
MPI2 0.25 [0.52] 2.43 [0.12] 0.012 0.50 [0.58] 2.16 [0.26] 0.022
1SPECT MPI ischaemia score: generalized linear model; 2myocardial ischaemia (pathologic MPI): logistic regression model; MPI — pathologic myocardial perfusion by MPI SPECT (SSS ≥ 4); 
SDS — Ischaemia reversibility scores, SDS = SSS – SRS; SEM — Standard Error of the Mean; SRS — Summed Rest Score; SSS — Summed Stress Score; SRS: Summed Rest Score;  
SDS — Ischemia reversibility scores, SDS = SSS-SRS; MPI— pathologic myocardial perfusion by MPI SPECT (SSS ≥ 4), SEM — Standard Error of the Mean.
However, an association between cardiovascular disease and 
psoriasis is detected most consistently among patients with severe 
psoriasis. A systematic review and meta-analysis in which classifi-
cation as severe psoriasis was based upon surrogate markers (e.g., 
a requirement for systemic treatment or hospital admission) found 
support for an increased risk for myocardial infarction, cardiovascu-
lar mortality, and stroke among patients with severe psoriasis [13]. 
In contrast to severe psoriasis, studies evaluating the relationship 
between milder disease and cardiovascular morbidity have yielded 
less consistent findings [14]. A longer duration of disease may be 
an additional risk factor for adverse cardiovascular events [15].
The rationale for a correlation between psoriasis and athero-
sclerotic disease is not well understood. Although the increased 
prevalence of main risk factors for cardiovascular disease, in 
patients with psoriasis likely contributes to the elevated risk for 
atherosclerosis, the role of chronic inflammation in the pathogen-
esis of both disorders may also be a key factor [16].
In a systematic review and meta-analysis that pooled the re-
sults of four studies, all-cause cardiovascular mortality was signif-
icantly greater in patients with severe psoriasis than in the general 
population [13]. A fifth study that reported a hazard ratio from 
the multivariate analysis offered additional support; the cohort 
study of approximately 3600 patients with moderate-to-severe 
psoriasis (defined as psoriasis treated with systemic therapy) and 
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14,330 control patients without a history of psoriasis, found that 
patients with severe psoriasis were more likely than controls to die 
from the cardiac or cerebrovascular disease [17, 18]. 
Our present MPI findings demonstrated that older patients with 
moderate-to-severe psoriasis exhibited significantly less reversible 
ischaemia at rest, compared to the control group. In the light of 
these observations, the question arises whether therapies with 
a systemic anti-inflammatory impact, like anti-tumour necrosis fac-
tor-alpha antibodies agents, might attenuate and eventually prevent 
the evolution of myocardial ischaemia as a function of disease 
duration and severity and ultimately reduce the MACE risk [16]. 
Conclusion
In summary, we found a similar rate of myocardial ischaemia 
during stress in patients with moderate-to-severe psoriasis com-
pared to control patients, but with less reversibility of ischaemia 
at rest. These findings are preliminary and their exact aetiology 
still unclear. The main limitation of this retrospective study is the 
small number of index patients. Larger, controlled studies are 
needed to verify our observations and inquire about the role 
of MPI studies in the evaluation of myocardial ischaemia in 
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